You are here

Article Text

Article menu
Download PDFPDF
Miscellanea
Letter
Local and systemic adverse effects to topical imiquimod due to systemic immune stimulation
  1. Bhushan Kumar1,
  2. Tarun Narang2
  1. 1Department of Dermatology, Venereology and Leprology, Silver Oaks Multispecialty Hospital, Mohali, Punjab, India
  2. 2Department of Dermatology, Venereology and Leprology, Gian Sagar Medical College and Hospital, Banur, Patiala, India
  1. Correspondence to Dr Professor Bhushan Kumar, Consultant Dermatologist, House no. 81, Sector 16 A, Chandigarh, India; kumarbhushan{at}hotmail.com

https://doi.org/10.1136/sextrans-2011-050025

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Imiquimod is a topical immune-response modifier with antitumour and antiviral properties. These actions of imiquimod are dependent on focal activation of the immune system and the overall shift in the cytokine profile results in promotion of type 1 T helper cell (Th1) response and inhibition of type 2 T helper cell (Th2) response.1

    We observed a few patients who had headache, arthralgias and fever while on treatment with imiquimod, which prompted us to conduct this prospective study regarding the safety and tolerability of imiquimod in patients with genital warts.

    In this prospective, intent-to-treat study, 22 immunocompetent men with genital warts were enrolled over a period …

    View Full Text

    Footnotes

    • Competing interests None.

    • Provenance and peer review Not commissioned; internally peer reviewed.